Abstract
Non-alcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of the metabolic syndrome and it affects more than 25% of the global population. Due to its complexity and still not completely elucidated underlying etiology, NAFLD remains without approved pharmacological treatment. Obesity and lipodystrophy are both associated with adipose tissue dysfunction and ectopic l…